Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Idexx Laboratories (IDXX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Idexx Laboratories (IDXX).
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pfizer (PFE)
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer today and set a price target of $34.00. The company’s shares closed last Monday at $26.77.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $29.07 average price target, which is a 7.5% upside from current levels. In a report issued on March 10, Scotiabank also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
Idexx Laboratories (IDXX)
In a report released today, Andrea Alfonso from UBS maintained a Hold rating on Idexx Laboratories, with a price target of $730.00. The company’s shares closed last Monday at $578.51.
According to TipRanks.com, Alfonso is ranked #2778 out of 12128 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idexx Laboratories with a $778.57 average price target.
Read More on PFE:
Disclaimer & DisclosureReport an Issue
- Pfizer price target raised to $36 from $35 at Guggenheim
- Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
- Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
- Pfizer (PFE) Balances Trial Setback With Quiet Pipeline Push
- Pfizer recommends shareholders reject mini-tender offer by Tutanota
